Rain Therapeutics to Present at IASLC 2021 World Conference on Lung Cancer and Participate in Panel Discussion at Citi 16th Annual Biopharma Virtual Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will be presenting a poster at the virtual IASLC 2021 World Conference on Lung Cancer (#WCLC21) being held September 8-14, 2021. Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will also participate in a Targeted Oncology Panel Discussion at the Citi 16th Annual Biopharma Conference being held September 8-10, 2021.

Additional details can be found below:

IASLC 2021 World Conference on Lung CancerPoster Title: The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesotheliomaPresenter: Lynn Heasley, Ph.D., University of Colorado Anschutz Medical CampusUnited States of America Date: Wednesday, September 8, 2021

Citi 16th Annual Biopharma Virtual Conference Targeted Oncology Panel DiscussionDate: Friday, September 10, 2021Time: 6:45 – 7:30 a.m. PTLocation: Company’s website (click here)

A copy of the poster and a replay of the panel discussion will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentations and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media ContactJordyn TemperatoLifeSci [e-mail]